A similar study of alternative Wnt pathway targeting agent ipafricept, a recombinant fusion protein comprised of the frizzled family receptor 8 fused to the human immunoglobulin Fc domain, in combination with nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic adenocarcinoma [22, 23] was also discontinued early for similar reasons, as were combination studies of ipafricept and vantictumab for other tumor types. This evidence concerns the gene FZD8 and neoplasm.